Supplementary Figure 1 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

Key Points

• CD8 T-cell dysfunction is driven by tumor-associated macrophages, leading to immunotherapy resistance.
• Key evidence suggests that interactions between macrophages and T-cells hinder effective immune response.
• The approach involves analyzing cohort selection and flow chart methodology related to immunotherapy outcomes.
• This highlights the need for new strategies to overcome therapy resistance related to macrophage-T cell interactions.

Abstract